Premium
PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL MALIGNANCIES INTOLERANT TO IBRUTINIB AND/OR ACALABRUTINIB
Author(s) -
Shadman M.,
Sharman J. P.,
Levy M. Y.,
Porter R.,
Zafar S. F.,
Burke J. M.,
Chaudhry A.,
Freeman B.,
Misleh J.,
Yimer H. A.,
Cultrera J. L.,
Guthrie T. H.,
Kingsley E.,
Rao S. S.,
Chen D. Y.,
Zhang X.,
Idoine A.,
Cohen A.,
Feng S.,
Huang J.,
Flinn I.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.42_2880
Subject(s) - ibrutinib , medicine , common terminology criteria for adverse events , discontinuation , adverse effect , mantle cell lymphoma , gastroenterology , progressive disease , neutropenia , waldenstrom macroglobulinemia , chronic lymphocytic leukemia , oncology , lymphoma , disease , chemotherapy , leukemia